

ADAP Medical Advisory Committee

October 19, 2022 Gathering Notes

1) Welcome and Rollcall

I. Welcome:

Meeting opened by Sharisse Kemp, ADAP Branch Chief

II. Introductions:

MAC Members, CDPH and Magellan introduced themselves

MAC Members in Attendance

Stephen O'Brien, Michelle Sherman, Danny Toub, Lucas Hill, David Grelotti, Laveeza Bhatti, David Lewis, Cliff Okada, Joanna Eveland, Glenn San Agustin

CDPH/Office of AIDS staff in Attendance

Philip Peters, Sharisse Kemp, Becca Parks, James Vo, Alejandro Contreras, Glorietta Kundeti

MAC Members not in Attendance

Wilbert Jordan, Laveeza Bhatti

Magellan Representatives in Attendance

Carrie Holden

2) ADAP / MAC Updates

I. Medications added to the ADAP formulary:

- Primaquine, rifapentine (priftin®), and rifaximin (xifaxan®) was added to the ADAP formulary.
- Management Memorandum 2022-13 released on the expanded indication for recombinant zoster vaccine (Shingrix) in people with HIV aged 18 and older.
- ADAP and PrEP-AP formularies was updated to remove Menactra and added MenQuadfi Meningococcal Conjugate Vaccine. Sanofi will be transitioning to MenQuadfi as their sole Meningococcal Conjugate Vaccine. A management memo will be released with further information on this update.
- Ethinyl estradiol and norethindrone contraceptive medications was added to the ADAP formulary. Management Memorandum 2022-16 released on Oct. 12, 2022.
- Lisinopril, benazepril, chlorthalidone, furosemide (Lasix®), hydrochlorothiazide (HCTZ), lisinopril plus HCTZ (Zestoretic®), losartan (Cozaar®) and losartan plus HCTZ (Hyzaar®) was added to the ADAP formulary. A management memo will be released with further information on this update.
- Vaxneuvance (PCV15), Prevnar 20 (PCV20) and new HBV vaccine (PreHevbrio) was added to the ADAP formulary.
- Apretude, diabetes and STI treatment medications is currently under the cost analysis process, and it is being reviewed to make sure the cost would not impose a significant burden on program.
- Monkeypox vaccine statement to be posted on CDPH website.

II. Medications removed from the ADAP formulary

- None

III. Update on the medications discussed during the July's 2022 MAC gathering:

- Diabetes medications are currently under the cost analysis process.

3) **Medication Discussion**

I. No new ARVs have received FDA approval

II. No public comments received

4) **PrEP-AP Formulary**

I. Lucas Hill discussion on:

- Medication-assisted treatment related to the PrEP-AP formulary.
 - Naltrexone
 - Buprenorphine

5) **Opportunistic Infection Treatments**

I. No new opportunistic infection discussion

6) **Magellan Rx Presentation**

I. Carrie Holden presented on:

- Long-Acting Injectable Antipsychotics

7) **Close of Meeting**

I. The next ADAP MAC gathering is scheduled for January 18, 2023, from 7:30 a.m. to 9:00 a.m.

8) **Action Items**

Action Items	Owners
Review fentanyl test strips for the ADAP formulary	James Vo

Action Items	Owners
Injectable Naltrexone to the PrEP-AP formulary	James Vo
COVID Therapeutic to commercial use	Dr. Peters